We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

SLAS Europe 2019 Conference and Exhibition

Where Discovery Meets Technology

  • Venue: Centre de Convencions Internacional de Barcelona | Barcelona, Spain.
  • Dates: Wednesday, June 26, 2019 – Friday, June 28, 2019

Bring your drug screening questions to Booth #515.
Participate in daily prize draws - and don´t forget to take a picture with us!
Promega frame


Tuesday, June 25

12:00-19:30: Outside SLAS Europe 2019 event
Bioluminescent Assays - What Can They Tell Us About Changes in Cancer and Immune Cell Metabolism?

Presented by: Reka Nagy, Strategic Collaboration Manager, Promega Switzerland
15th European Functional Drug Screen Symposium - Hospital de Sant Pau, Barcelona

Better understanding the role of cell metabolism in cancer, immunology, obesity, diabetes, and neurodegenerative disease presents specific research challenges, which drive the need for more rapid and reliable methods for measuring changes in metabolic pathways. Metabolites produced by the major metabolic pathways serve as signaling molecules and link the metabolic state of a cell to transcriptional control, epigenetics and cell signaling. Therefore, the ability to measure changes in key metabolites rapidly and robustly in higher throughput formats should provide a powerful approach for establishing the links between cellular metabolism and cell function under normal and disease conditions. Utilizing novel pro-luciferin substrate that in the presence of NAD(P)H is converted to luciferin and light production by luciferase, we developed a core technology for measuring key energy co-factors (NAD(P)/NAD(P)H) and extended it to multiple metabolite (glucose, lactate, glutamine, glutamate, glycerol, triglycerides) or enzyme activity assays. Here we demonstrate applicability of those assays to various formats and samples using multiple automation platforms, including collecting the samples at different time points and performing multiple assays from the same sample. We also show examples on setting up HTS screens for two major metabolic pathways in cancer cells, glycolysis and glutaminolysis, and identifying the difference in metabolic activity between highly invasive SKOV-3 versus low invasive OVCAR-3 ovarian cancer cells.
10:00-17:00: SLAS Europe 2019, Short Course Programme - Room 120
Assay Guidance Workshop for High-Throughput Screening and Lead Discovery

Presented by: Terry Riss, Global Strategic Marketing Manager, Promega Corporation

Treating Cells as Reagents to Design Reproducible Screening Assays

This full-day workshop will cover a broad range of critical concepts underlying assay development for high throughput screening (HTS) and lead discovery projects. Many of the methodologies successfully implemented in such projects have been "tribal knowledge" within the pharmaceutical industry and not readily found in a classroom or the literature. This "tribal knowledge" has been developed for decades into detailed chapters within the Assay Guidance Manual (AGM) to facilitate reproducible assays that can identify the most promising compounds for development of molecular probes or clinical candidates for drug discovery and development. An increasing number of researchers are actively developing well validated assays for drug discovery that include phenotypic and biochemical assays for lead optimization. This workshop is designed to disseminate critical information about the implementation of robust assay methods and intended to benefit the entire drug discovery community. Many of the workshop instructors have 20-30 years of experience in the field of drug discovery.
10:00-17:00: SLAS Europe 2019, Short Course Programme - Room 121
3D Culture Models and Organoids for Drug Discovery

Presented by: Terry Riss, Global Strategic Marketing Manager, Promega Corporation

Validating Cell Health Assays Applied to 3D Cultures

Cell-based in vitro assays are used throughout the drug discovery and development chain, allowing for high-throughput efficacy but also mechanistic-based toxicity testing. A big challenge, however, is the translation of in vitro assays toward the in vivo outcome. Physiological relevance is a key parameter to improve the predictive power of cell-based assays. The better we can reflect tissue architecture, composition and function, the more predictive an in vitro assay will become. The 3D course covers advances in 3D cell culture technologies, assays and their use in drug discovery and development.

Thursday, June 27

8:30-9:30: SLAS Europe 2019, Exhibitor Tutorial - Room 119
Monitoring Functional Mechanisms of Protein Degradation using Promega´s Toolbox

Presented by: Steve Edenson, Strategic Collaboration Manager, Promega Corporation

Targeted protein degradation therapies represent an expanding area of drug development

Small molecule PROTAC compound libraries require sensitive screening technologies that can quickly and clearly report on the cellular steps required for PROTAC-mediated degradation. Using bioluminescence resonance energy transfer with NanoLuc and HaloTag fusions, termed NanoBRET, we can monitor changes in interactions of proteins targeted for degradation, including dynamic recruitment to E3 ligases and real-time trafficking to the 26S proteasome after treatment with inhibitors or PROTAC compounds.
10:30-12:45: SLAS Europe 2019, Advances in Experimental Drug Discovery Track, New Approaches
in Target Discovery Session - Room 112
A Homogeneous Bioluminescent Immunoassay Approach to Interrogate Cellular Signaling Pathways Activation and Deactivation

Presented by: Hicham Zegzouti, Sr. Research Scientist, Promega Corporation

Novel Bioluminescent Cell-based Immunoassay Approach

Immunoassays such as ELISA and Western blots are routinely used for protein detection and PTM analysis (e.g phosphorylation). Although sensitive, these methods are tedious, require multiple washing steps, and not easily adaptable to HTS. I will describe a novel bioluminescent NanoBiT cell-based immunoassay approach which takes less than two hours to complete in a homogeneous “Add and Read” format. We validated this platform by monitoring the activation of multiple signaling pathways through specific nodes of phosphorylation (e.g pIkB, pAKT, and pSTAT3). We tested different small or large molecule inhibitors of these pathways and obtained the expected pharmacology. Other advantages of this bioluminescent approach include no cell engineering as the phosphorylation of endogenous substrate is detected in any cell type. This new technology can be adapted to any signaling pathway node, allowing scientists to streamline the analysis of signaling pathways of interest during drug discovery.


A Homogeneous Bioluminescent Immunoassay Approach to Interrogate Cellular Signaling Pathways Activation and Deactivation
Presented by: Hicham Zegzouti, Sr Research Scientist, Promega Corporation

Quantitative Live-Cell Characterization of PROTAC-Induced Degradation and Mechanism of Action
Presented by:  Steve Edenson, Strategic Collaboration Manager, Promega Corporation

A Homogeneous Bioluminescence Cell-Specific Cytotoxicity Assay for Surveying Cellular Sub-Populations in Mixed Cultures
Presented by: Richard Somberg, Director--Pharma/Biotech Market Segment, Promega Corporation

Learn more: Poster Searching by Keywords


Share With a Friend

We will NOT sell your personal information, such as your name or email address, to third parties or use your email address to send you marketing materials. The email and names entered will only be used to identify the sender and recipient of the email.

Send Cancel